Global Generic Injectables Market 2009-15

  • ID: 1411531
  • October 2010
  • Region: Global
  • 20 Pages
  • Avalon Global Research
1 of 3

As majority of the blockbuster drugs are set to go off patent in the next few years, $140 bn injectables market is set to assume prominence as the fastest growing and the most preferred drug delivery mode in place of oral formulations. Relatively high insulation from competition post off- patent stage, strong entry barriers, high profit margin and drug effectiveness are making injectables more popular than oral formulations.

We have employed a combination of secondary research and in depth interviews with key players to validate our findings and further understand the underlying trends and strategies. Extensive triangulation has been done to categorize and estimate the injectables market data.

In this report, we have focused on the bright prospects of $17.5 bn generic injectables sub segment which is expected to witness a compounded annual growth of 15% over the next five years. We expect a market opportunity of USD 1.6 bn to open up for the generic injectables in the regulated markets following the drugs going off patent. Further, we see a strong business case for collaboration of global and regional players in the injectables segment to expand the market. The market READ MORE >

Note: Product cover images may vary from those shown
2 of 3

1. Background and Definitions

2. Market Size and Segmentation
2.1 Global Market Size
2.2 Generic and Innovator Injectable Markets
2.3 Market Breakdown by Product Segments
2.4 Geographic Breakdown – Global Injectables Market
2.5 Therapeutic Breakdown – Global Injectables Market
2.6 Respiratory Injectables Market
2.7 Ophthalmological Injectables Market
2.8 Key Players – Global Injectables Market

3. Future Trends

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown





Our Clients

  • Pall Corporation
  • Ferring Pharmaceuticals B.V.
  • Medtronic, Inc.
  • SkyePharma AG
  • Heron Therapeutics, Inc.
  • NIPRO Medical Corporation